La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
GlaxoSmithKline Pharmaceuticals Crescita futura
Future criteri di controllo 5/6
GlaxoSmithKline Pharmaceuticals prevede che gli utili e i ricavi cresceranno rispettivamente di 25.4% e 10.2% all'anno. Si prevede che l'EPS crescerà di 18.8% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 39.1% in 3 anni.
Informazioni chiave
25.4%
Tasso di crescita degli utili
18.8%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 18.5% |
| Tasso di crescita dei ricavi | 10.2% |
| Rendimento futuro del capitale proprio | 39.1% |
| Copertura analitica | Low |
| Ultimo aggiornamento | 10 Oct 2024 |
Aggiornamenti recenti sulla crescita futura
The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 05
Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Feb 15Recent updates
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease
Aug 29The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 05Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%
Jun 01With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case
May 05GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear
Apr 14Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Feb 15Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?
Jan 18GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected
Dec 28Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today
Oct 05Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?
Sep 12GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet
Mar 17Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?
Sep 02GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly
Mar 02The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On
Mar 20Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?
Feb 27Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?
Feb 06What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?
Jan 11
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain
Dec 06Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts
Nov 01Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield
Oct 29What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?
Sep 29If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today
Aug 30Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?
Aug 02It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend
Jul 12Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?
Jul 07Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 3/31/2026 | 41,906 | 10,116 | 10,219 | N/A | 3 |
| 3/31/2025 | 37,559 | 8,538 | 7,526 | N/A | 4 |
| 6/30/2024 | 35,067 | 6,400 | N/A | N/A | N/A |
| 3/31/2024 | 34,537 | 5,900 | 5,508 | 5,820 | N/A |
| 12/31/2023 | 33,114 | 5,289 | N/A | N/A | N/A |
| 9/30/2023 | 33,084 | 6,478 | 6,449 | 6,890 | N/A |
| 6/30/2023 | 32,683 | 6,237 | N/A | N/A | N/A |
| 3/31/2023 | 32,517 | 6,076 | 4,402 | 4,842 | N/A |
| 12/31/2022 | 32,739 | 4,195 | N/A | N/A | N/A |
| 9/30/2022 | 32,875 | 3,940 | 3,786 | 4,133 | N/A |
| 6/30/2022 | 33,048 | 3,897 | N/A | N/A | N/A |
| 3/31/2022 | 32,780 | 3,808 | 7,761 | 8,107 | N/A |
| 12/31/2021 | 34,861 | 5,100 | N/A | N/A | N/A |
| 9/30/2021 | 34,708 | 4,962 | 7,912 | 8,354 | N/A |
| 6/30/2021 | 33,403 | 3,684 | N/A | N/A | N/A |
| 3/31/2021 | 29,256 | 2,873 | 5,337 | 5,779 | N/A |
| 12/31/2020 | 31,609 | 4,819 | N/A | N/A | N/A |
| 9/30/2020 | 30,823 | -3,358 | 3,860 | 5,419 | N/A |
| 6/30/2020 | 30,850 | 905 | N/A | N/A | N/A |
| 3/31/2020 | 32,244 | 932 | 3,346 | 4,905 | N/A |
| 12/31/2019 | 31,994 | 1,019 | N/A | N/A | N/A |
| 9/30/2019 | 32,461 | 8,768 | 2,845 | 5,758 | N/A |
| 6/30/2019 | 31,804 | 4,749 | N/A | N/A | N/A |
| 3/31/2019 | 31,281 | 4,454 | 1,182 | 4,095 | N/A |
| 3/31/2018 | 28,715 | 3,507 | N/A | 4,728 | N/A |
| 3/31/2017 | 29,085 | 3,368 | N/A | 2,344 | N/A |
| 3/31/2016 | 28,379 | 3,761 | N/A | 1,389 | N/A |
| 3/31/2015 | 26,384 | 3,811 | N/A | 2,701 | N/A |
| 12/31/2013 | 25,597 | 4,817 | N/A | 2,813 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: La crescita prevista degli utili di GLAXO ( 23% all'anno) è superiore al tasso di risparmio ( 6.7% ).
Guadagni vs Mercato: Si prevede che gli utili di GLAXO ( 23% all'anno) cresceranno più rapidamente del mercato Indian ( 16.9% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di GLAXO cresceranno in modo significativo nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di GLAXO ( 10.2% all'anno) crescerà più rapidamente del mercato Indian ( 10.1% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di GLAXO ( 9.7% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di GLAXO sarà elevato tra 3 anni ( 39.1 %)